150
Participants
Start Date
December 1, 2021
Primary Completion Date
May 30, 2027
Study Completion Date
September 7, 2027
NMS-03305293
Route of administration: Oral
Temozolomide
"Route of administration: Oral~Commercially available temozolomide"
Erasmus Medical Center, Rotterdam
University Hospital Zurich, Zurich
Memorial Sloan-Kettering Cancer Center, New York
Istituto Clinico Humanitas, Rozzano
IRCCS Istituto Neurologico Carlo Besta, Milan
University of Virginia Health System, Charlottesville
Mayo Clinic Florida, Jacksonville
Istituto Oncologico Veneto - IRCCS, Padua
IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna
Mayo Clinic Cancer Center, Rochester
UT Southwestern Medical Center, Dallas
The University of Texas MD Anderson Cancer Center, Houston
University of Utah, University Hospital, Salt Lake City
Mayo Clinic Hospital - Phoenix, Phoenix
University of California Irvine Medical Center (UCIMC) - Chao Family Comprehensive Cancer Center, Orange
Swedish Medical Center - First Hill Campus, Seattle
Dana-Farber Cancer Institute, Boston
PanOncology Trials (Pan American Center for Oncology Trials, LLC), Rio Piedras
Lead Sponsor
Nerviano Medical Sciences
INDUSTRY